- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-FGF23/ ADHR/ FGFN functional antibody
Anti-FGF23/ ADHR/ FGFN functional antibody for cell culture, ELISA & in-vivo assay
Go to FGF23/FGF23 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T14853-Ab-1/ GM-Tg-hg-T14853-Ab-2 | Anti-Human FGF23 monoclonal antibody | Human |
| GM-Tg-rg-T14853-Ab-1/ GM-Tg-rg-T14853-Ab-2 | Anti-Rat FGF23 monoclonal antibody | Rat |
| GM-Tg-mg-T14853-Ab-1/ GM-Tg-mg-T14853-Ab-2 | Anti-Mouse FGF23 monoclonal antibody | Mouse |
| GM-Tg-cynog-T14853-Ab-1/ GM-Tg-cynog-T14853-Ab-2 | Anti-Cynomolgus/ Rhesus macaque FGF23 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T14853-Ab-1/ GM-Tg-felg-T14853-Ab-2 | Anti-Feline FGF23 monoclonal antibody | Feline |
| GM-Tg-cang-T14853-Ab-1/ GM-Tg-cang-T14853-Ab-2 | Anti-Canine FGF23 monoclonal antibody | Canine |
| GM-Tg-bovg-T14853-Ab-1/ GM-Tg-bovg-T14853-Ab-2 | Anti-Bovine FGF23 monoclonal antibody | Bovine |
| GM-Tg-equg-T14853-Ab-1/ GM-Tg-equg-T14853-Ab-2 | Anti-Equine FGF23 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T14853-Ab-1/ GM-Tg-hg-T14853-Ab-2; GM-Tg-rg-T14853-Ab-1/ GM-Tg-rg-T14853-Ab-2; GM-Tg-mg-T14853-Ab-1/ GM-Tg-mg-T14853-Ab-2; GM-Tg-cynog-T14853-Ab-1/ GM-Tg-cynog-T14853-Ab-2; GM-Tg-felg-T14853-Ab-1/ GM-Tg-felg-T14853-Ab-2; GM-Tg-cang-T14853-Ab-1/ GM-Tg-cang-T14853-Ab-2; GM-Tg-bovg-T14853-Ab-1/ GM-Tg-bovg-T14853-Ab-2; GM-Tg-equg-T14853-Ab-1/ GM-Tg-equg-T14853-Ab-2 |
| Products Name | Anti-FGF23 monoclonal antibody |
| Format | mab |
| Target Name | FGF23 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-FGF23 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-ab-086 | Pre-Made Burosumab biosimilar, Whole mAb, Anti-FGF23 Antibody: Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC therapeutic antibody |
| Target Antigen | GM-Tg-g-T14853-Ag-1 | Recombinant multi-species FGF23/ ADHR/ FGFN protein |
| Cytokine | GM-Tg-g-T14853-Ag-1 | fibroblast growth factor 23 (FGF23) protein |
| ORF Viral Vector | pGMAD000303 | human FGF23 Adenovirus plasmid |
| ORF Viral Vector | vGMAD000303 | human FGF23 Adenovirus particle |
| ORF Viral Vector | pGMLPm004536 | mouse Fgf23 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm004536 | mouse Fgf23 Lentivirus particle |
Target information
| Target ID | GM-T14853 |
| Target Name | FGF23 |
| Gene ID | 8074,64654,170583,710643,611773,101100063,530239,100058460 |
| Gene Symbol and Synonyms | ADHR,FGF23,Fgf8b,FGFN,HFTC2,HPDR2,HYPF,PHPTC |
| Uniprot Accession | Q9GZV9,Q8VI82 |
| Uniprot Entry Name | FGF23_HUMAN,FGF23_RAT |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target, INN Index, Cytokine Target |
| Disease | Hypertension, Localized osteoporosis [Lequesne] |
| Gene Ensembl | ENSG00000118972 |
| Target Classification | N/A |
The target: FGF23, gene name: FGF23, also named as ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC. This gene encodes a member of the fibroblast growth factor family of proteins, which possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. The product of this gene regulates phosphate homeostasis and transport in the kidney. The full-length, functional protein may be deactivated via cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in this gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC). [provided by RefSeq, Feb 2013].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
